IDEXX LABORATORIES INC DE
For the period ended Dec 31, 2024. Filed Feb 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 21, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IDEXX LABORATORIES, INC. | |
| By: /s/ Jonathan J. Mazelsky | |
| Date: February 21, 2025 | Jonathan J. Mazelsky |
|---|---|
| President and Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:
| SIGNATURE | TITLE | DATE | ||
|---|---|---|---|---|
| /s/ Jonathan J. Mazelsky | President, Chief Executive Officer and Director (Principal Executive Officer) | February 21, 2025 | ||
| Jonathan J. Mazelsky | ||||
| /s/ Brian P. McKeon | Executive Vice President, Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer) | February 21, 2025 | ||
| Brian P. McKeon | ||||
| /s/ Lawrence D. Kingsley | Non-Executive Board Chair | February 21, 2025 | ||
| Lawrence D. Kingsley | ||||
| /s/ Irene Chang Britt | Director | February 21, 2025 | ||
| Irene Chang Britt | ||||
| /s/ Bruce L. Claflin | Director | February 21, 2025 | ||
| Bruce L. Claflin | ||||
| /s/ Stuart M. Essig, PhD | Director | February 21, 2025 | ||
| Stuart M. Essig, PhD | ||||
| /s/ Daniel M. Junius | Director | February 21, 2025 | ||
| Daniel M. Junius | ||||
| /s/ Sam A. Samad | Director | February 21, 2025 | ||
| Sam A. Samad | ||||
| /s/ M. Anne Szostak | Director | February 21, 2025 | ||
| M. Anne Szostak | ||||
| /s/ Sophie V. Vandebroek, PhD | Director | February 21, 2025 | ||
| Sophie V. Vandebroek, PhD | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.